CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 111 enrolled
Drug / intervention
Travoprost 0.004% Ophthalmic Solution (Travatan) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00763061
NCT00763061Phase 4Completed
CompareCT.gov

A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research·interventional·Posted Sep 30, 2008·Updated Mar 2, 2010

In Brief

A Phase 4 clinical trial evaluating Travoprost 0.004% Ophthalmic Solution (Travatan) and Timolol 0.5% Ophthalmic Solution (Timoptic) for Glaucoma. Completed, enrolled 111 participants across 1 site.

Detailed Summary

To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 30, 2008
Enrollment StartMay 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.8 years ago

Interventions

Travoprost 0.004% Ophthalmic Solution (Travatan)drug

Travoprost at 9 AM + Placebo \& 9 PM

Timolol 0.5% Ophthalmic Solution (Timoptic)drug

Timolol in each eye, twice daily at 9 AM \& 9 PM